EP0031
EP0031 is an experimental small-molecule drug from Ellipses Pharma in phase 2 trials for non-small-cell lung cancer, aimed at RET.
Overview
EP0031 is a small-molecule drug developed by Ellipses Pharma. Its target is RET (the sponsor names RET). ClinicalTrials.gov describes the intervention as: EP0031 is a potent next-generation selective RET-inhibitor (SRI). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer. The largest, NCT05443126, plans to enrol 265 participants with primary completion expected 2027-03. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"EP0031" OR ABSTRACT:"EP0031") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about EP0031, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentEP0062
Shares Ellipses Pharma and the tags pipeline, ctgov-ingest.
- TreatmentVRN110755
Shares Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentSSGJ-706
Shares Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentBA3071
Shares Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentJS111
Shares Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentAL2846
Shares RET and the tags pipeline, ctgov-ingest.
- TreatmentDJI136
Shares Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentJYP0015
Shares Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.